Integrating in vivo Molecular Imaging 

Day 1  |  Day 2  |  Download Brochure 


In Vivo Molecular Imaging in Drug Discovery & Development conference aims to bring together a unique mix of those with and without expertise in imaging to explore and assess the impact that integrating in vivo imaging is having in drug discovery today. Industry case studies will showcase examples of where imaging has been pivotal in advancing a project from preclinical to clinical, including target validation and work with siRNA and biologics. We will review how useful molecular imaging has been in making decisions on the value of biomarkers used in translational science and what impact this has had on discovery and development of novel therapeutics. We will explore how different companies integrate imaging and run imaging in their discovery groups – the formation of cross functional teams and management of large volumes of data and data files will be examined. 




12:30 pm Registration


1:55 Chairperson’s Opening Remarks

Thomas Krucker, Ph.D., Head, Molecular Imaging, Global Imaging Group, Novartis Institutes for Biomedical Research, Inc.


2:00 Keynote Presentation: Imaging Biomarkers in Drug Development

Jeffrey EvelhochJeffrey Evelhoch, Ph.D., Vice President, Exploratory & Translational Sciences; Head, Imaging, Merck Research Laboratories

In the development of novel therapeutics, biomarkers can provide information critical to both internal decision-making and establishing efficacy and/or safety for regulatory approval as a substitute for a clinical characteristic or variable reflecting patient feeling, function or survival (i.e., a surrogate endpoint). Imaging is a powerful biomarker that can provide information about genetic, biochemical, physiological and anatomic processes in many diseases including multiple sclerosis, cancer, arthritis, atherosclerosis, Alzheimer’s disease, and others. This talk will explain why biomarkers are needed, how imaging is used as a biomarker and give several examples of how imaging biomarkers impact decision-making in drug development.

2:30 Successfully Integrating Molecular Imaging into Drug Discovery and Development

Thomas Krucker, Ph.D., Head, Molecular Imaging, Global Imaging Group, Novartis Institutes for Biomedical Research, Inc.

Technologies in the field of molecular imaging are evolving rapidly and are readily accessible. The challenge remains to choose and combine imaging modalities, biological, and chemical tools to timely and successfully address the critical questions in early and late drug discovery. Concepts and applications of ways molecular imaging can be used in a unique fashion to accelerate drug discovery and support drug development will be discussed.

Sponsored by
3:00 NanoSPECT/CT Imaging of Bispecific Molecular Liver Targeting for Treatment of Hepatitis C

Stephen Mather, Ph.D., Professor, Centre for Molecular Oncology, Barts Cancer Institute
In-vivo imaging of radiolabelled bispecific fusion proteins shows that delivery of Interferon alpha to the liver is significantly enhanced by fusion to a high affinity asialoglycroprotein targeting human domain antibody.

3:30 Networking Refreshment Break in the Exhibit Hall 

4:30 The Expanding Role of Imaging for Assessment of Proof-of-Concept in Pharma- and Bio-Therapeutic Drug Discovery and Development

Thomas Bocan, Ph.D., Senior Director & Head, Pre-Clinical BioImaging Center, Worldwide Research and Development, Pfizer, Inc.

Multi-modality, platform, imaging approaches are more widely used to demonstrate target organ uptake, target binding and pharmacologic modulation. Imaging has evolved from the measurement of structural endpoints to assessment of functional changes, e.g., blood flow, metabolism, proliferation, and/or platform biomarkers of disease, e.g., islet cell/AD marker. With broadening of the pharmacologic tools into novel biologic agents, imaging applications for assessment of proteins, antibodies and antibody fragments, siRNA and stem cells are evolving. Platform imaging tools applied both pre-clinically and clinically have the potential to aid reduce compound attrition.

5:00 Multiplexed Molecular Imaging; Rational Design of the Next Generation of Informative Molecular Imaging Probes

Hisataka Kobayashi, M.D., Ph.D., Chief Scientist, Molecular Imaging Program, NCI/NIH

Current generation of molecular probes are monochromatic (yielding only one signal per molecule) and always on. Therefore, images are constructed with linear and single parametric data, creating difficulties in achieving adequate target to background ratios. The ability to generate polychromatic and activatable imaging probes will be the next major challenge in optimizing molecular imaging probes. In this talk, designing strategies for new-generation molecular imaging probes will be discussed from two different aspects; wavelength (physics) and physical scale (biology and chemistry).

5:30 End of Day


Day 1  |  Day 2  |  Download Brochure 

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  



WPC Quotes